Bar-Sela G, Kaplan-Cohen V, Ilan N, Vlodavsky I, Ben-Izhak O
Department of Oncology, Rambam Medical Centre, Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa.
Histopathology. 2006 Aug;49(2):188-93. doi: 10.1111/j.1365-2559.2006.02469.x.
To determine the expression and prognostic significance of heparanase in nasopharyngeal carcinoma (NPC).
Immunohistochemistry was performed on formalin-fixed paraffin-embedded sections of 46 patients with NPC. Clinical and immunohistochemical data were correlated with gender, age, histological type, Epstein-Barr virus (EBV) status, stage and survival.
Heparanase immunoreactivity was found in 35% (16/46) of specimens. The cumulative survival of patients diagnosed as heparanase negative (n = 30) at 10 years was 70%. In contrast, the cumulative survival of patients diagnosed as heparanase positive (n = 16) at 10 years was 25%, differences that are highly statistically significant (P = 0.03). No significant correlations were found between heparanase immunoreactivity and gender, age, EBV status, tumour histology or tumour stage.
Heparanase expression is inversely correlated with survival of NPC patients, clearly indicating that heparanase is a reliable prognostic factor for this malignancy, and further supports the notion that heparanase is a valid target for the development of anti-cancer drugs.
确定乙酰肝素酶在鼻咽癌（NPC）中的表达及其预后意义。
对46例鼻咽癌患者的福尔马林固定石蜡包埋切片进行免疫组织化学检测。将临床和免疫组织化学数据与性别、年龄、组织学类型、爱泼斯坦-巴尔病毒（EBV）状态、分期及生存率进行关联分析。
在35%（16/46）的标本中发现了乙酰肝素酶免疫反应性。诊断为乙酰肝素酶阴性（n = 30）的患者10年累积生存率为70%。相比之下，诊断为乙酰肝素酶阳性（n = 16）的患者10年累积生存率为25%，差异具有高度统计学意义（P = 0.03）。未发现乙酰肝素酶免疫反应性与性别、年龄、EBV状态、肿瘤组织学或肿瘤分期之间存在显著相关性。
乙酰肝素酶表达与鼻咽癌患者的生存率呈负相关，明确表明乙酰肝素酶是这种恶性肿瘤的可靠预后因素，并进一步支持了乙酰肝素酶是抗癌药物开发有效靶点的观点。
